Biotech News

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion (BMEA)Biomea Fusion2026-03-31 11:00 ESTClinical readout

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif.,

Open original release

Related news

BMEABiomea Fusion2026-05-05 21:51 EST

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

ZNTLZentalis2026-05-05 12:00 EST

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

EXELExelixis2026-05-19 12:00 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

REGNRegeneron Pharmaceuticals2026-05-16 00:19 EST

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

TEVATeva Pharmaceutical Industries2026-06-18 20:57 EST

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

View all latest news

Biomea Fusion

Biomea Fusion is a metabolic-disease and oncology biotech built around covalent inhibitor chemistry. Its pipeline is focused on diseases where precision small-molecule design can matter.

Recent company news

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-05-05 21:51 EST

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

BMEABiomea Fusion2026-04-27 21:37 EST

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

BMEABiomea Fusion2026-03-31 11:00 EST

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Stock data

Close: 1.26 USD
Market cap: 99.05M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States